{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055028","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.696483+00:00","generated_at":"2026-06-16T02:29:14.922140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rigel Pharma Q1 net loss narrows to $13.5M; TAVALISSE sales up 38% to $22.3M","bullets":["Net loss of $13.5M ($0.08/sh) improved from $27.4M ($0.16) in Q1 2022.","Total revenue $26.1M: TAVALISSE $22.3M (+38% YoY), REZLIDHIA $1.5M (first full quarter).","Shipped 2,256 TAVALISSE bottles to patients (highest quarter); 109 REZLIDHIA bottles shipped.","Accessed $20M term loan from MidCap; cash and investments $58.7M as of March 31.","Partner Kissei launched TAVALISSE in Japan; Lilly to begin Phase 2a trial of R552 in RA in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055028","json":"https://secwatch.observer/filing/0001104659-23-055028.json","markdown":"https://secwatch.observer/filing/0001104659-23-055028.md","text":"https://secwatch.observer/filing/0001104659-23-055028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/0001104659-23-055028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/tm2314346d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:29:14.922140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3423f2f864d9fad867a57ef409af9f33105aff44","claim":"RIGEL PHARMACEUTICALS INC reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 2, 2023, Rigel Pharmaceuticals, Inc. (“Rigel”) announced certain financial results for its first quarter ended March 31, 2023. A copy of Rigel’s press release, titled “Rigel Reports First Quarter 2023 Financial Results and Provides Business Update,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923055028/0001104659-23-055028-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}